Alnylam Pharmaceuticals reported a significant slowdown in demand for its main product, Amvuttra, which makes up 87.5% of its sales. The company's U.S. transthyretin treatment revenue grew by $81 million in Q3 2026, down from $129 million the previous quarter. Following this announcement, Alnylam's stock price fell 25.13% to $174.00. Pomerantz LLP is investigating potential securities fraud by Alnylam and its executives related to this disclosure, advising affected investors to contact them for possible legal action.
While Alnylam Pharmaceuticals' stock price dropped sharply by 25.13% following its earnings news, on Pluang it trades at USD 160.18 as of Nov 12, 2026 22:11 WIB, showing a modest 0.21% gain for the day. This price remains close to its 52-week low of USD 151.64 and far from its 52-week high of USD 473.29, highlighting the stock's significant volatility over the past year. The typical hold time on Pluang is 41 days, indicating relatively short-term investor interest in this health sector stock.
